Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

The Company Remains Focused on the Goal of Establishing ZURZUVAE as the Standard of Care for Women with Postpartum Depression CAMBRIDGE, Mass., January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, ...

The Company Remains Focused on the Goal of Establishing ZURZUVAE as the Standard of Care for Women with Postpartum Depression Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage” or “the Company ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

Biogen and Sage co-developed Zurzuvae, which was approved by the FDA for PPD in August 2023. Sage has experienced several setbacks since this approval. Zurzuvae did not win approval as a treatment ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...